229 related articles for article (PubMed ID: 20055093)
1. Development of idarubicin and doxorubicin solid lipid nanoparticles to overcome Pgp-mediated multiple drug resistance in leukemia.
Ma P; Dong X; Swadley CL; Gupte A; Leggas M; Ledebur HC; Mumper RJ
J Biomed Nanotechnol; 2009 Apr; 5(2):151-61. PubMed ID: 20055093
[TBL] [Abstract][Full Text] [Related]
2. Reversion of Multidrug Resistance by Co-Encapsulation of Doxorubicin and Metformin in Poly(lactide-co-glycolide)-d-α-tocopheryl Polyethylene Glycol 1000 Succinate Nanoparticles.
Shafiei-Irannejad V; Samadi N; Salehi R; Yousefi B; Rahimi M; Akbarzadeh A; Zarghami N
Pharm Res; 2018 Apr; 35(6):119. PubMed ID: 29671072
[TBL] [Abstract][Full Text] [Related]
3. Idarubicin overcomes P-glycoprotein-related multidrug resistance: comparison with doxorubicin and daunorubicin in human multiple myeloma cell lines.
Roovers DJ; van Vliet M; Bloem AC; Lokhorst HM
Leuk Res; 1999 Jun; 23(6):539-48. PubMed ID: 10374847
[TBL] [Abstract][Full Text] [Related]
4. Rational Design of Multifunctional Polymeric Nanoparticles Based on Poly(l-histidine) and d-α-Vitamin E Succinate for Reversing Tumor Multidrug Resistance.
Li Z; Chen Q; Qi Y; Liu Z; Hao T; Sun X; Qiao M; Ma X; Xu T; Zhao X; Yang C; Chen D
Biomacromolecules; 2018 Jul; 19(7):2595-2609. PubMed ID: 29618203
[TBL] [Abstract][Full Text] [Related]
5. Idarubicin-loaded methoxy poly(ethylene glycol)-
Liang B; Li N; Zhang S; Qi A; Feng J; Jing W; Shi C; Ma Z; Gao S
Int J Nanomedicine; 2019; 14():543-556. PubMed ID: 30666113
[TBL] [Abstract][Full Text] [Related]
6. Micelles of d-α-Tocopheryl Polyethylene Glycol 2000 Succinate (TPGS 2K) for Doxorubicin Delivery with Reversal of Multidrug Resistance.
Hao T; Chen D; Liu K; Qi Y; Tian Y; Sun P; Liu Y; Li Z
ACS Appl Mater Interfaces; 2015 Aug; 7(32):18064-75. PubMed ID: 26214761
[TBL] [Abstract][Full Text] [Related]
7. Antitumor activity of idarubicin, a derivative of daunorubicin, against drug sensitive and resistant P388 leukemia.
Tsuruo T; Oh-Hara T; Sudo Y; Naito M
Anticancer Res; 1993; 13(2):357-61. PubMed ID: 8517647
[TBL] [Abstract][Full Text] [Related]
8. Vinflunine (20',20'-difluoro-3',4'-dihydrovinorelbine), a novel Vinca alkaloid, which participates in P-glycoprotein (Pgp)-mediated multidrug resistance in vivo and in vitro.
Etievant C; Barret JM; Kruczynski A; Perrin D; Hill BT
Invest New Drugs; 1998; 16(1):3-17. PubMed ID: 9740539
[TBL] [Abstract][Full Text] [Related]
9. pH-Responsive therapeutic solid lipid nanoparticles for reducing P-glycoprotein-mediated drug efflux of multidrug resistant cancer cells.
Chen HH; Huang WC; Chiang WH; Liu TI; Shen MY; Hsu YH; Lin SC; Chiu HC
Int J Nanomedicine; 2015; 10():5035-48. PubMed ID: 26346762
[TBL] [Abstract][Full Text] [Related]
10. Simultaneous delivery of anti-miR21 with doxorubicin prodrug by mimetic lipoprotein nanoparticles for synergistic effect against drug resistance in cancer cells.
Rui M; Qu Y; Gao T; Ge Y; Feng C; Xu X
Int J Nanomedicine; 2017; 12():217-237. PubMed ID: 28115844
[TBL] [Abstract][Full Text] [Related]
11. Doxorubicin-loaded solid lipid nanoparticles to overcome multidrug resistance in cancer therapy.
Kang KW; Chun MK; Kim O; Subedi RK; Ahn SG; Yoon JH; Choi HK
Nanomedicine; 2010 Apr; 6(2):210-3. PubMed ID: 20060074
[TBL] [Abstract][Full Text] [Related]
12. Bioactive lipids-based pH sensitive micelles for co-delivery of doxorubicin and ceramide to overcome multidrug resistance in leukemia.
Wang Y; Ding Y; Liu Z; Liu X; Chen L; Yan W
Pharm Res; 2013 Nov; 30(11):2902-16. PubMed ID: 23793993
[TBL] [Abstract][Full Text] [Related]
13. Breast cancer targeted chemotherapy based on doxorubicin-loaded bombesin peptide modified nanocarriers.
Wang C; Sun X; Wang K; Wang Y; Yang F; Wang H
Drug Deliv; 2016 Oct; 23(8):2697-2702. PubMed ID: 26203692
[TBL] [Abstract][Full Text] [Related]
14. Olmutinib Reverses Doxorubicin Resistance in ETS1-Overexpressing Leukemia Cells.
Zhong J; Zhang J; Yu X; Zhang X; Dian L
Med Sci Monit; 2020 Aug; 26():e924922. PubMed ID: 32830792
[TBL] [Abstract][Full Text] [Related]
15. TPGS functionalized mesoporous silica nanoparticles for anticancer drug delivery to overcome multidrug resistance.
Zhao P; Li L; Zhou S; Qiu L; Qian Z; Liu X; Cao X; Zhang H
Mater Sci Eng C Mater Biol Appl; 2018 Mar; 84():108-117. PubMed ID: 29519418
[TBL] [Abstract][Full Text] [Related]
16. Molecular mechanism study of chemosensitization of doxorubicin-resistant human myelogenous leukemia cells induced by a composite polymer micelle.
Han M; Diao YY; Jiang HL; Ying XY; Chen DW; Liang WQ; Gao JQ
Int J Pharm; 2011 Nov; 420(2):404-11. PubMed ID: 21945184
[TBL] [Abstract][Full Text] [Related]
17. Partial circumvention of P-glycoprotein-mediated multidrug resistance by doxorubicin-14-O-hemiadipate.
Leontieva OV; Preobrazhenskaya MN; Bernacki RJ
Invest New Drugs; 2002 Feb; 20(1):35-48. PubMed ID: 12003193
[TBL] [Abstract][Full Text] [Related]
18. Overexpression of P-glycoprotein and alterations in topoisomerase II in P388 mouse leukemia cells selected in vivo for resistance to mitoxantrone.
Kamath N; Grabowski D; Ford J; Kerrigan D; Pommier Y; Ganapathi R
Biochem Pharmacol; 1992 Sep; 44(5):937-45. PubMed ID: 1356339
[TBL] [Abstract][Full Text] [Related]
19. Comparison of mechanisms responsible for resistance to idarubicin and daunorubicin in multidrug resistant LoVo cell lines.
Toffoli G; Simone F; Gigante M; Boiocchi M
Biochem Pharmacol; 1994 Nov; 48(10):1871-81. PubMed ID: 7986198
[TBL] [Abstract][Full Text] [Related]
20. Liposomal doxorubicin circumvents PSC 833-free drug interactions, resulting in effective therapy of multidrug-resistant solid tumors.
Krishna R; Mayer LD
Cancer Res; 1997 Dec; 57(23):5246-53. PubMed ID: 9393743
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
